{'fraction_non_alphanumeric': 0.024346257889990983, 'fraction_numerical': 0.033363390441839495, 'mean_word_length': 4.577889447236181, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Survey of current practices from the International Stereotactic Body Radiotherapy Consortium (ISBRTC) for head and neck cancers.

AIM
To provide a multi-institutional description of current practices of stereotactic body radiotherapy (SBRT) for head and neck cancer.


MATERIALS & METHODS
15 international institutions with significant experience in head and neck SBRT were asked to complete a questionnaire covering clinical and technical factors.


RESULTS
SBRT is used 10-100% of the time for recurrent primary head and neck cancer, and 0-10% of the time in newly diagnosed disease. Five centers use a constraint for primary disease of 3-5 cm and 25-30 cc. Nine institutions apply a clinical target volume expansion of 1-10 mm and 14 use a planning target volume margin of 1-5 mm. Fractionation regimens vary between 15 and 22 Gy in 1 fraction to 30-50 Gy in 5 or 6 fractions. The risk of carotid blowout quoted in the re-irradiation setting ranges from 3 to 20%.


CONCLUSION
There is considerable heterogeneity in patient selection and techniques in head and neck SBRT practice among experienced centers.